CAPLIPOINT
Caplin Point Laboratories Limited (CAPLIPOINT) Stock Analysis
Caplin Point Laboratories Limited is an Indian pharmaceutical company focused on niche generics and exports. It markets injectables and oral products in Latin America, Africa, and other emerging markets. A lean operating model supports growth from India. The company is listed on Indian stock exchanges and is headquartered in India.
Healthcare › Drug Manufacturers - Specialty & Generic
₹2,338.20
-11.74% 1W | +19.80% 52W
Market Cap
17.8k CR
P/E Ratio
26.8
52W High
₹2990
52W Low
₹1500.3
Div. Yield
0.34%
Beta
0.4
50 DMA
₹2638.4
200 DMA
₹2138.7
Profit Margin
29.1%
Inst. Own.
5.7%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 395 | 410 | 436 | 453 | 459 | 483 | 493 | 502 | 510 | 534 | 543 | 600 | 610 |
| Expenses | 269 | 273 | 293 | 308 | 307 | 318 | 331 | 334 | 332 | 345 | 353 | 396 | 397 |
| Operating Profit | 127 | 137 | 142 | 145 | 152 | 165 | 162 | 168 | 178 | 189 | 190 | 204 | 213 |
| OPM % | 32% | 34% | 33% | 32% | 33% | 34% | 33% | 33% | 35% | 35% | 35% | 34% | 35% |
| Other Income | 12 | 21 | 17 | 17 | 19 | 21 | 31 | 26 | 23 | 30 | 34 | 28 | 34 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 11 | 12 | 14 | 16 | 16 | 17 | 16 | 17 | 16 | 18 | 19 | 19 | 22 |
| Profit before tax | 127 | 146 | 145 | 146 | 154 | 168 | 177 | 177 | 184 | 201 | 204 | 213 | 225 |
| Tax % | 18% | 20% | 18% | 17% | 19% | 22% | 21% | 18% | 18% | 20% | 19% | 19% | 20% |
| Net Profit | 104 | 116 | 120 | 121 | 125 | 131 | 140 | 145 | 151 | 160 | 166 | 173 | 179 |
| EPS in Rs | 13.62 | 15.13 | 15.43 | 16.01 | 16.31 | 17.21 | 18.28 | 18.76 | 20.10 | 20.32 | 21.56 | 22.38 | 23.27 |
| Metric | Jun 2015 | Mar 20169m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 252 | 239 | 402 | 540 | 649 | 863 | 1,061 | 1,269 | 1,467 | 1,694 | 1,937 | 2,187 | 2,287 |
| Expenses | 192 | 175 | 276 | 345 | 417 | 603 | 732 | 874 | 1,025 | 1,142 | 1,287 | 1,422 | 1,491 |
| Operating Profit | 60 | 64 | 125 | 195 | 232 | 260 | 329 | 395 | 442 | 552 | 651 | 765 | 797 |
| OPM % | 24% | 27% | 31% | 36% | 36% | 30% | 31% | 31% | 30% | 33% | 34% | 35% | 35% |
| Other Income | 3 | 4 | 10 | 13 | 19 | 41 | 23 | 38 | 55 | 66 | 92 | 111 | 126 |
| Interest | 1 | 0 | 1 | 1 | 1 | 0 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 8 | 7 | 13 | 19 | 23 | 32 | 37 | 47 | 45 | 53 | 66 | 73 | 78 |
| Profit before tax | 53 | 60 | 121 | 188 | 227 | 269 | 314 | 386 | 451 | 564 | 677 | 803 | 844 |
| Tax % | 23% | 24% | 21% | 23% | 22% | 20% | 20% | 20% | 16% | 18% | 20% | 19% | |
| Net Profit | 41 | 46 | 96 | 145 | 177 | 215 | 251 | 308 | 377 | 461 | 541 | 650 | 678 |
| EPS in Rs | 5.43 | 6.05 | 12.65 | 19.15 | 23.35 | 28.42 | 32.03 | 39.56 | 49.57 | 60.19 | 70.56 | 84.36 | 87.53 |
| Dividend Payout % | 18% | 20% | 12% | 10% | 9% | 9% | 9% | 10% | 9% | 8% | 8% | 9% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 14.0% | 16.0% | 25.0% |
| Profit CAGR | 19.0% | 21.0% | 30.0% |
Shareholding Pattern
Promoters70.56%
FIIs6.16%
DIIs2.22%
Public21.06%
Promoters70.57%
FIIs6.51%
DIIs2.10%
Public20.82%
Promoters70.57%
FIIs6.58%
DIIs2.05%
Public20.81%
Promoters70.57%
FIIs6.15%
DIIs2.14%
Public21.14%
Promoters70.57%
FIIs5.76%
DIIs2.49%
Public21.19%
Promoters70.66%
FIIs2.36%
DIIs0.64%
Public26.33%
Promoters70.62%
FIIs3.33%
DIIs1.08%
Public24.95%
Promoters70.56%
FIIs5.73%
DIIs2.00%
Public21.72%
Promoters70.57%
FIIs6.15%
DIIs2.14%
Public21.14%
Promoters70.57%
FIIs5.76%
DIIs2.49%
Public21.19%
CAPLIPOINT
Holdings Analysis
Key strengths & risk signals
77
Overall
79
Fundamental
75
Technical
Risks (3)
NEGLIGIBLE DIVIDEND! 0.33% yield - little to no income.
RECOVERY MODE! Current price (2361.6) above 200-day but below 50-day.
NEGATIVE MOMENTUM! Price declined across timeframes - down 11.9% (1 week), 14.3% (1 month), 10.8% (3 months).
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (2641.4) is above 200-day average (2135.8) - positive signal.
BULLISH SENTIMENT! In last 30 days: 15 up days, 15 down days. Avg volume on up days: 399,626 vs down days: 150,605. Ratio: 2.65x
LOW VOLATILITY! Beta of 0.40 - stable stock, less market risk.
Fundamental & Technical Analysis
76Overall
79Fundamental
73Technical
Fundamental Breakdown
Growth Quality
24/30
Revenue CAGR: 14.3% (GOOD, 11/15). Profit CAGR: 19.4% (VERY GOOD, 13/15).
Profit Margin
9/10
EXCELLENT EFFICIENCY! 29.1% profit margin - company keeps strong profits.
PEG Valuation
9/10
FAIRLY VALUED! PEG of 1.38 indicates reasonable valuation.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.34% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 26.44% public ownership - balanced ownership structure.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (2638.4) is above 200-day average (2138.7) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (2338.2) above 200-day but below 50-day.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
6/10
POSITIVE YEAR! Stock gained 19.8% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 14 up days, 16 down days. Avg volume on up days: 421,560 vs down days: 147,974. Ratio: 2.85x
RSI
4/5
APPROACHING OVERSOLD! RSI at 30.9 - watch for reversal.
52W Range
3/5
MID RANGE! Trading at 56.2% of 52W range - neutral zone.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 11.7% (1 week), 15.1% (1 month), 12.5% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.40 - stable stock, less market risk.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAPLIPOINT | ₹2,338.20 | 26.8 | 29.1% | 14.3% | 19.4% | +19.8% | 76 | BREAKDOWN | +15.8% | +4.0% | +19.6% | +1.7% |
| COHANCE | ₹445.60 | 163.2 | 5.0% | 18.3% | -24.2% | -48.9% | 58 | CONSOLIDATING DOWN | -149.3% | -223.0% | -23.1% | -31.8% |
| SHILPAMED | ₹962.10 | 67.9 | 17.7% | 13.8% | – | +173.0% | 66 | BREAKDOWN | +115.1% | -6.4% | +44.9% | +6.6% |
| ALIVUS | ₹1,348.00 | 27.5 | 23.3% | 6.9% | 6.5% | +44.0% | 70 | APPROACHING RESISTANCE | +31.8% | -1.6% | +6.4% | -7.1% |
| ERIS | ₹1,149.60 | 24.5 | 20.0% | 23.3% | 17.5% | -27.0% | 64 | BREAKDOWN | +20.7% | -49.4% | +12.6% | +15.5% |
| APLLTD | ₹792.50 | 22.7 | 8.9% | 9.5% | 25.4% | -14.0% | 74 | CONSOLIDATING UP | +12.1% | -14.6% | +25.7% | +16.4% |
| JUBLPHARMA | ₹938.90 | 42.4 | 4.1% | 9.8% | – | -12.4% | 54 | BREAKDOWN | -45.1% | -52.7% | +18.2% | -2.2% |
| ASTRAZEN | ₹5,950.50 | 87.7 | 7.0% | 31.3% | 23.6% | -35.3% | 56 | APPROACHING SUPPORT | -32.1% | -15.6% | +29.7% | +18.0% |
Data from TradeAlone · Updated daily
CAPLIPOINT News
Caplin Point Laboratories Limited (CAPLIPOINT) breaks below support, falls 5%2026-08-12Caplin Point Laboratories Limited (CAPLIPOINT) gains 5% intraday2026-07-27Caplin Point Laboratories Limited (CAPLIPOINT) cools off after resistance breakout, down 5%2026-07-22Caplin Point Laboratories Limited (caplipoint) Gets USFDA Approval for Foscarnet Sodium Injection2026-05-14
